The value of the calcium binding protein S100 in the management of patients with traumatic brain injury

Acta Biomedica

Volumn 83, Issue 1, 2012, Pages 5-20

  Schiavi, Paolo ^a,b   Iaccarino, Corrado ^a,b   Servadei, Franco ^a,b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Biomarkers; Brain damage; CT; Mild TBI; Outcome; Paediatric; S100; Traumatic brain injury

Indexed keywords

PROTEIN S 100; PROTEIN S100B;

CEREBROSPINAL FLUID; DISEASE SEVERITY; HUMAN; PROTEIN BLOOD LEVEL; REVIEW; TRAUMATIC BRAIN INJURY;

BRAIN INJURIES; CRANIOCEREBRAL TRAUMA; HUMANS; S100 PROTEINS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84864219136     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. Kramer F, Milting H. Novel biomarkers in human terminal heart failure and under mechanical circulatory support. Biomarkers 2011; Suppl 1: 31-41.
2. Kovesdi E, Liickl J, Bukovics P, et al. Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. Acta Neurochir (Wten) 2010; 152: 1-17.
3. Servadei F, Teasdale G, Murray G, et al. Defining acute mild head injury in adults: a proposal based on prognostic factors, diagnosis, and management. J Neurotrauma 2001; 18: 257-64.
4. Stein SC, Fabbri A, Servadei F. Routine serial computed tomographic scans in mild traumatic brain injury: when are they cost-effective? J Trauma 2008; 65: 66-72.
5. Pandor A, Goodacre S, Harnan S, et al. Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation. Health Technol Assess 2011; 15: 1-283.
6. Feng ST, Law MW, Huang B, et al. Radiation dose and cancer risk from pediatric CT examinations on 64-slice CT: a phantom study. Eur J Radiol 2010; 76:19-23.
7. Kuppermann N, Holmes JF, Dayan PS, et al. Pediatric Emergency Care Applied Research Network (PECARN). Identification of children at very low risk of clinically-important brain injuries after head trauma: a prospective cohort study. Lancet 2009; 374:1160-70.
8. Osmond MH, Klassen TP, Wells GA, et al. Pediatric Emergency Research Canada (PERC) Head Injury Study Group. CATCH: a clinical decision rule for the use of computed tomography in children with minor head injury. CMAJ 2010; 182: 341-8.
9. Brenner DJ. Estimating cancer risks from pediatric CT: going from the qualitative to the quantitative. Pediatr Radiol 2002; 32: 228-3;
10. Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. Am J Roentgenol 2001; 176: 289-96. (Pubitemid 32105628)
11. Hall P, Adami H, Trichopoulos D, et al. Effect of low doses of ionising radiation in infancy on cognitive function in adulthood: Swedish population based cohort study. BMJ 2004; 328: 19.
12. Ingebrigtsen T, Romner B, Kongstad P, Langbakk B. Increased serum concentrations of S-100 after minor head injury. A biochemical marker with prognostic value ? J Neurol Neurosurg Psychiatry 1995; 59: 103-104.
13. Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain? J Neurosci Res 2007; 85:1373-80. (Pubitemid 46724380)
14. Yardan T, Erenler AK, Baydin A, Aydin K, Cokluk C. Usefulness of S100B protein in neurological disorders. J Pak MedAssoc 2011; 61:276-81.
15. Bloomfield SM, McKinneyJ, Smith L, Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care 2007; 6:121-38. (Pubitemid 46934023)
16. Ishiguro Y, Kato K, Ito T, Nagaya M. Determination of three enolase isoenzymes and S100 protein in various tumors in children. Cancer Res 1983; 43: 6080-4. (Pubitemid 14212683)
17. Hayashi K, Hoshida Y, Horie Y, et al. Immunohistochemical study on the distribution of alpha and beta subunits of S-100 protein in brain tumors. Acta Neuropathol (Berl) 1991; 81: 657-63.
18. Hachitand Y, Nakagawara A, Negoshi M, et al. Prognostic value of N-myc oncogene amplification and S-100 protein positivity in children with neuroblastic tumors. Acta Pathol Jpn 1992; 42: 639-44.
19. Donato R. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. IntJBiochem Cell Biol 2001; 33: 637-68. (Pubitemid 32520962)
20. Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci 2002; 7: 1356-68.
21. Heizmann C. Ca2 + -binding S100 proteins in the central nervous system. Neurochem Res 1999; 24:1097-100. (Pubitemid 29413597)
22. Fano G, Biocca S, Fulle S, et al.The S-100: a protein family in search of a function. Progress Neurobiol 1995; 46: 71-82.
23. Zimmer D, Cornwall E, Landar A, et al. The S100 protein family: history, function, and expression. Brain Res Bull 1995; 37: 417-29.
24. Whitaker-Azmitia PM, Wingate M, Borella A, Gerlai R, Roder J, Azmitia EC. Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndrome. Brain Res 1997; 776: 51-60. (Pubitemid 28018457)
25. Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003; 60: 614-32.
26. Korfias S, Stranjalis G, Papadimitriou A, et al. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem 2006; 13: 3719-31. (Pubitemid 44873741)
27. Barger S, Van Eldik L. S100 beta stimulates calcium fluxes in glial and neuronal cells. J Biol Chem 1992; 267: 9689-94.
28. Selinfreund R, Barger S, Pledger W, et al. Neurotrophic protein S100 beta stimulates glial cell proliferation. Proc Natl Acad Sci USA 1991; 88: 3554-3508.
29. Scotto C, Deloulme J, Rousseau D, et al. Calcium and S100B regulation of p53-dependent cell growth arrest and apoptosis. Mol Cell Biol 1998; 18: 4272-81. (Pubitemid 28287950)
30. Marshak D. S-100 beta as a neurotrphic factor. Prog Brain Res 1990; 86:169-81.
31. Janeczko K. The proliferative response of S-100 proteinpositive glial cells to injury in the neonatal rat brain. Brain Res 1991; 564: 86-90.
32. Takana H, Akari M, MasuzawaT. Reaction of astrocytes in gerbil hippocampus following transient ischemia: immunohistochemical observations with antibodies against glial fibrillary acidic protein, gluatime synthesase and S-100 protein. Exp Neurol 1992; 116: 264-74.
33. Petzold A, Keir G, Lim D, et al. CSF and serum S100B: release and wash-out pattern. Brain Res Bull 2003; 61:281- 5. (Pubitemid 36952474)
34. Jonsson H, Johnsson P, Hoglund P, et al. Elimination of S100B and renal function after cardiac surgery. J Cardiothras Vasc Anesth 2000; 6: 698-701.
35. Jackson RG, Samra GS, Radcliffe J, et al. The early fall in levels of S-lOOb in traumatic brain injury. Clin Chem Lab Med 2000; 38:1165-7. (Pubitemid 32007775)
36. Beaudeux L, Leger P, Dequen P, et al. Influence of hemolysis on the measurement of S-100B protein and neuron specific enolase plasma concentrations during coronary artery bypass grafting. Clin Chem 2000; 46: 989-90. (Pubitemid 30461269)
37. Wiesmann M, Missler U, Gottmann D, Gehring S. Plasma S-100b protein concentration in healthy adults is age- and sex-independent. Clin Chem 1998; 44:1056-8. (Pubitemid 28213152)
38. Stiell IG, Lesiuk H, Wells GA, et al. Canadian CT head rule study for patients with minor head injury: methodology for phase II (validation and economic analysis). Ann Emerg Med 2001; 38: 317-22. (Pubitemid 32822545)
39. Cushman JG, Agarwal N, Fabian TC, et al. Practice management guidelines for the management of mild traumatic brain injury: the EAST practice management guidelines work group. J Trauma 2001; 51:1016-26. (Pubitemid 33117476)
40. Stein SC, Burnett MG, Glick HA. Indications for CT scanning in mild traumatic brain injury: a cost-effectiveness study. J Trauma 2006; 61: 558-66. (Pubitemid 44400931)
41. Unden J, Romner B. Can low serum levels of S100B predict normal CT findings after minor head injury in adults?: an evidence-based review and meta-analysis. J Head Trauma Rehabil 2010; 25: 228-40.
42. Morochovic R, Racz O, Kitka M, et al. Serum S100B protein in early management of patients after mild traumatic brain injury. Eur J Neurol 2009; 16: 1112-7.
43. Naeimi ZS, Weinhofer A, Sarahrudi K, et al. Predictive value of S-100B protein and neuron specific-enolase as markers of traumatic brain damage in clinical use. Brain Inj 2006 May; 20: 463-8. (Pubitemid 43832387)
44. Unden J , Bellner J , Astrand R, Romner B. Serum S100B levels in patients with epidural haematomas. Br J Neurosurg 2005; 19: 43-5. (Pubitemid 40824372)
45. IngebrigtsenT, Romner B, Marup-Jensen S, et al.The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study. Brain Inj 2000; 14:1047-55. (Pubitemid 32013963)
46. Biberthaler P, MussackT, Wiedemann E, et al. Evaluation of S-100b as a specific marker for neuronal damage due to minor head trauma. World J Surg 2001; 25: 93-7. (Pubitemid 32422226)
47. Mussack T, Biberthaler P, Kanz KG, et al. Immediate S- 100B and neuron-specific enolase plasma measurements for rapid evaluation of primary brain damage in alcohol-intoxicated, minor head-injured patients. Shock 2002; 18: 395-400.
48. Biberthaler P,Mussack T,Wiedemann E, et al. Rapid identification of high-risk patients after minor head trauma (MHT) by assessment of S-100B: ascertainment of a cutoff level. Eur J Med Res 2002; 7:164-170.
49. Biberthaler P, MussackT, Kanz KG, et al. Identification of high-risk patients after minor craniocerebral trauma. Measurement of nerve tissue protein S 100. Unfallchirurg 2004; 107:197-202. (Pubitemid 38495878)
50. De Boussard C, Fredman P, Lundin A, Andersson K, Edman G, Borg J . S100 in mild traumatic brain injury. Brain Inj 2004; 18: 671-83. (Pubitemid 38735473)
51. Biberthaler P, Linsenmeier U, Pfeifer KJ, et al. Serum S- 100B concentration provides additional information for the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock 2006; 25: 446-53.
52. Bazarian J J, Beck C, Blyth B, von Ahsen N, Hasselblatt M. Impact of creatine kinase correction on the predictive value of S-100B after mild traumatic brain injury. Restor Neurol Neurosci 2006; 24:163-72. (Pubitemid 44081717)
53. Poli-de-Figueiredo LF, Biberthaler P, Simao Filho C, Hauser C, Mutschler W, J ochum M. Measurement of S- 100B for risk classification of victims sustaining minor head injury-first pilot study in Brazil. Clinics (Sao Paulo) 2006; 61:41-6. (Pubitemid 43578795)
54. Miiller K.Townend W, Biasca N, et al. SIOOB serum level predicts computed tomography findings after minor head injury. J Trauma 2007; 62:1452-6. (Pubitemid 46918752)
55. Bouvier D, Oddoze C, Ben Haim D, et al. Interest of S100B protein blood level determination for the management of patients with minor head trauma. Ann Biol Clin (Paris) 2009; 67: 425-31.
56. MussackT, Biberthaler P, Wiedemann E, et al. S-100b as a screening marker of the severity of minor head trauma (MHT)-a pilot study. ActaNeurochir Suppl 2000; 76: 393-6.
57. de Kruijk J R, Leffers P, Menheere P.P.C.A, Meerhoff S, Twijnstra A. S-100B and neuron-specific enolase in serum of mild traumatic brain injury patients A comparison with healthy controls. Acta Neurol Scand 2001; 103:175-179. (Pubitemid 32158440)
58. Savola O, Hillbom M. Early predictors of post-concussion symptoms in patients with mild head injury. Eur J Neurol 2003; 10:175-81. (Pubitemid 36308213)
59. Stranjalis G, Korfias S, Papapetrou C, et al. Elevated serum S-100B protein as a predictor of failure to short-term return to work or activities after mild head injury. J Neurotrauma 2004; 21:1070-5. (Pubitemid 39096857)
60. de Boussard CN, Lundin A, Karlstedt D, Edman G, Bartfai A, Borg J. S100 and cognitive impairment after mild traumatic brain myiry. J Rebabil Med 2005; 37: 53-7. (Pubitemid 40214509)
61. Stapert S, de Kruijk J , Houx P, Menheere P, Twijnstra A, J olles J. S-100B concentration is not related to neurocognitive performance in the first month after mild traumatic brain injury. Eur Neurol 2005; 53: 22-6. (Pubitemid 40522827)
62. Sojka P, Stilnacke BM, Bjornstig U, Karlsson K. One-year follow-up of patients with mild traumatic brain injury: occurrence of post-traumatic stress-related symptoms at follow-up and serum levels of Cortisol, S-100B and neuron- specific enolase in acute phase. Brain Inj 2006; 20: 613-20. (Pubitemid 43878693)
63. Bazarian J J, Zemlan FP, Mookerjee S, Stigbrand T. Serum S-100B and cleaved-tau are poor predictors of long-term outcome after mild traumatic brain injury. Brain Inj 2006; 20: 759-65. (Pubitemid 43994844)
64. Lima DP, Simao Filho C, Abib Sde C, de Figueiredo LF. Quality of life and neuropsychological changes in mild head trauma. Late analysis and correlation with S100B protein and cranial CT scan performed at hospital admission. Injury 2008; 39: 604-11.
65. Bouzat P, Francony G, Declety P, et al. Can serum protein S100 beta predict neurological deterioration after moderate or minor traumatic brain injury? Ann Fr Anesth Reanim 2009; 28:135-9.
66. Kleinert K, Schleich F, Biasca N, Simmen HP. Is there a correlation between S100 beta and post-concussion symptoms after mild traumatic brain injury? Zentralbl Chir 2010; 135: 277-8.
67. Ruan S, Noyes K, Bazarian J J. The economic impact of S-100B as a pre-head CT screening test on emergency department management of adult patients with mild traumatic brain injury. J Neurotrauma 2009; 26: 1655-64.
68. Bohmer AE, Oses J P, Schmidt AP, et al. Neuron-Specific Enolase, S100B, and Glial Fibrillary Acidic Protein levels as outcome predictors in patients with severe traumatic brain injury. Neurosurgery 2011; 68:1624-31.
69. Honda M.Tsuruta R, KanekoT, et al. Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic brain injury in humans compared with S-100B and neuronspecific enolase. J Trauma 2010; 69:104-9.
70. Olivecrona M, Rodling-Wahlstrom M, Naredi S, Koskinen LO. S-100B and neuron specific enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. J Neurol Neurosurg Psychiatry 2009; 80: 1241-7.
71. Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 2004; 21:1553-61. (Pubitemid 39525165)
72. Raabe A, Seifert V. Protein S-100B as a serum marker of brain damage in severe head injury: preliminary results. Neurosurg Rev 2000; 23:136-8.
73. Rothoerl RD, Woertgen C, Brawanski A. S-100 serum levels and outcome after severe head injury. Acta Neurochir Suppl 2000; 76: 97-100.
74. Pleines UE, Morganti-Kossmann MC, Rancan M, J oller H, Trentz O, Kossmann T. S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma 2001; 18: 491-8. (Pubitemid 32472839)
75. Woertgen C, Rothoerl RD, Brawanski A. Early S-100B serum level correlates to quality of life in patients after severe head injury. Brain Inj 2002; 16: 807-16.
76. Hu DL, Liu XH, Yu XL, et al. Clinical significance of serum S-100B protein in severe cerebral injury. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2004; 16: 221-2.
77. Vos PE, Lamers KJ, Hendriks J C, et al Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004; 62: 1303-10. (Pubitemid 38526041)
78. Li N, Shen J K, Zhao WG, Cai Y, Li YF, Zhan SK. S-100B and neuron specific enolase in outcome prediction of severe head injury. Chin J Traumatol 2004; 7:156-8. (Pubitemid 38786904)
79. Hayakata T, Shiozaki T, Tasaki O, et al. Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock 2004; 22:102-7. (Pubitemid 40228186)
80. Ucar T, Baykal A, Akyuz M, Dosemeci L, Toptas B. Comparison of serum and cerebrospinal fluid protein S-100b levels after severe head injury and their prognostic importance. J Trauma 2004; 57: 95-8. (Pubitemid 39079236)
81. da Rocha AB, Schneider RF, de Freitas GR, et al. Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males. Clin Chem Lab Med 2006; 44:1234-42. (Pubitemid 44580806)
82. Rainey T, Lesko M, Sacho R, Lecky F, Childs C. Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24h) timepoint. Resuscitation 2009; 80: 341-5.
83. Murillo-Cabezas F, Munoz-Sanchez MA, Rincón-Ferrari MD, et al. The prognostic value of the temporal course of S100 beta protein in post-acute severe brain injury: a prospective and observational study. Brain Inj 2010; 24: 609-19.
84. Vos PE, J acobs B, Andriessen TM, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 2010; 75:1786-93.
85. Dimopoulou I, Korfias S, Dafni U, et al. Protein S-100b serum levels in trauma-induced brain death. Neurology 2003; 60: 947-51. (Pubitemid 36348926)
86. Korfias S, Stranjalis G, Boviatsis E, et al. Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med 2007; 33: 255-60. (Pubitemid 46221230)
87. Nylén K, Ost M, Csajbok LZ, et al. Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien). 2008; 150; 221-7.
88. Stein DM, Kufera J A, Lindell A, et al. Association of CSF biomarkers and secondary insults following severe traumatic brain injury. Neurocrit Care 2011; 14: 200-7.
89. Petzold A, Green AJ, Keir G, et al. Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: a pilot study. Crit Care Med 2002; 30: 2705-10. (Pubitemid 36870573)
90. Watt SE, Shores EA, Baguley IJ, Dorsch N, Fearnside MR. Protein S-100 and neuropsychological functioning following severe traumatic brain injury. Brain Inj 2006; 20:1007-17. (Pubitemid 44596866)
91. Wiesmann M, Steinmeier E, Magerkurth O, Linn J , Gottmann D, Missler U. Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP. Acta Neurol Scand 2010; 121:178-85.
92. Herrmann M, Curio N, J ost S, et al. Release of biochemical markers of damage to neuronal and glial brain tissue is associated with short and long term neuropsychological outcome after traumatic brain injury. J Neurol Neurosurg Psychiatry 2001; 70: 95-100. (Pubitemid 32096128)
93. Schiiltke E, Sadanand V, Kelly ME, Griebel RW, J uurlink BH. Can admission S-lOObeta predict the extent of brain damage in head trauma patients? Can J Neurol Sci 2009; 36: 612-6.
94. Marshall LF, Marshall SB, Klauber MR, et al. A new classification of head injury based on computerized tomography. J Neurosurgery 1991; Vol 75 N.1 suppl: 14-20.
95. Townend W, Ingebrigtsen T. Head injury outcome prediction: a role for protein S-100B? Injury 2006; 37:1098-108. (Pubitemid 44765014)
96. Lo TY, J ones PA, Minns RA. Combining coma score and serum biomarker levels to predict unfavorable outcome following childhood brain trauma. J Neurotrauma 2010; 27: 2139-45.
97. Kirchhoff C, Buhmann S, Braunstein V, et al. Cerebrospinal slOO-B: a potential marker for progressive intracranial hemorrhage in patients with severe traumatic brain injury. Eur J Med Res 2008; 13: 511-6.
98. Castellani C, Bimbashi P, Ruttenstock E, Sacherer P, Stojakovic T, Weinberg AM. Neuroprotein s-100b - a useful parameter in paediatric patients with mild traumatic brain injury? Acta Paediatr 2009; 98:1607-12.
99. Hallen M, Karlsson M, Carlhed R, Hallgren T, Bergenheim M. S-100B in serum and urine after traumatic head injury in children. J Trauma 2010; 69: 284-9.
100. Akhtar J I, Spear RM, Senac MO, Peterson BM, Diaz SM. Detection of traumatic brain injury with magnetic resonance imaging and S-100B protein in children, despite normal computed tomography of the brain. Pediatr Crit Care Med 2003; 4: 322-6.
101. Bechtel K, Frasure S, Marshall C, Dziura J , Simpson C. Relationship of serum S100B levels and intracranial injury in children with closed head trauma. Pediatrics 2009; 124: 697-704.
102. Geyer C, Ulrich A, Grafe G, Stach B, Till H. Diagnostic value of S100B and neuron-specific enolase in mild pediatric traumatic brain injury. J Neurosurg Pediatr 2009 Oct;4(4):339-44.
103. Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM. Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg 2005; 103: 61-8. (Pubitemid 44954950)
104. Berger RP, Pierce MC, Wisniewski SR, et al. Neuronspecific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics 2002; 109: E31
105. Beers SR, Berger RP, Adelson PD. Neurocognitive outcome and serum biomarkers in inflicted versus non-inflicted traumatic brain injury in young children. J Neurotrauma 2007; 24: 97-105. (Pubitemid 46214415)
106. Gazzolo D, Michetti F, Bruschettini M, et al. Pediatric concentrations of S100B protein in blood: age- and sexrelated changes. Clin Chem 2003; 49: 967-70. (Pubitemid 36623482)
107. Castellani C, Stojakovic T, Cichocki M, et al. Reference ranges for neuroprotein S-100B: from infants to adolescents. Clin Chem Lab Med 2008; 46:1296-9.
108. Berger RP, Beers SR, Richichi R, Wiesman D, Adelson PD. Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J Neurotrauma 2007; 24: 1793-801.
109. Spinella PC, Dominguez T, Drott HR, et al. S-100beta protein-serum levels in healthy children and its association with outcome in pediatric traumatic brain injury. Crit Care Med 2003; 31: 939-45. (Pubitemid 36379608)
110. Berger RP, Kochanek PM. Urinary S100B concentrations are increased after brain injury in children: a preliminary study. Pediatr Crit Care Med 2006;7: 557-61. (Pubitemid 44715295)
111. Bahloul M, Ben Hamida C, Chelly H, et al. Severe head injury among children: prognostic factors and outcome. Injury 2009; 40: 535-540.
112. Gill M.Windemuth R, Steele R, Green SM. A comparison of the Glasgow Coma Scale score to simplified alternative scores for the prediction of traumatic brain injury outcomes. Ann Emerg Med 200S; 45: 37-42. (Pubitemid 40051165)
113. Haukoos J S, Gill MR, Rabon RE, Gravitz CS, Green SM. Validation of the Simplified Motor Score for the prediction of brain injury outcomes after trauma. Ann Emerg Med2007; 50:18-24. (Pubitemid 46908933)
114. White J R, Farukhi Z, Bull C, et al. Predictors of outcome in severely head-injured children. Crit Care Med 2001;29: 534-540. (Pubitemid 32225294)
115. Healey C, Osier TM, Rogers FB, et al. Improving the Glasgow Coma Scale score: motor score alone is a better predictor. J Trauma 2003; 54: 671-678.
116. Korfias S, Stranjalis G, Psachoulia C, et al. Slight and short-lasting increase of serum S-100B protein in extracranial trauma. Brain Inj 2006; 20: 867-72. (Pubitemid 44594166)
117. MussackT, Kirchhoff C, Buhmann S, et al. Significance of Elecsys S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients. Clin Chem Lab Med 2006; 44:1140-5. (Pubitemid 44370938)
118. Pelinka LE, Toegel E, Mauritz W, Redl H. Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma. Shock 2003; 19:195-200.
119. Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G. High serum S100B levels for trauma patients without head injuries. Neurosurgery 2001; 48: 1255-8.
120. Unden J , Bellner J , Eneroth M, Ailing C, Ingebrigtsen T, Romner B. Raised serum S100B levels after acute bone fractures without cerebral injury. J Trauma 2005; 58: 59-61. (Pubitemid 40221734)
121. Savola O, Pyhtinen J , Leino TK, Siitonen S, Niemela O, Hillbom M. Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma 2004; 56:1229-34. (Pubitemid 38901833)
122. Stalnacke BM, Ohlsson A,Tegner Y, Sojka P. Serum concentrations of two biochemical markers of brain tissue damage S-100B and neurone specific enolase are increased in elite female soccer players after a competitive game. Br J Sports Med 2006; 40: 313-6.
123. Stalnacke BM, Tegner Y, Sojka P. Playing ice hockey and basketball increases serum levels of S-100B in elite players: a pilot study. Clin J Sport Med 2003; 13: 292-302. (Pubitemid 37210524)
124. Bazarian J J, Beck C, Blyth B, von Ahsen N, Hasselblatt M. Impact of creatine kinase correction on the predictive value of S-100B after mild traumatic brain injury. Restor NeurolNeurosci 2006; 24:163-72. (Pubitemid 44081717)
125. Routsi C, Stamataki E, Nanas S, et al. Increased levels of serum S100B protein in critically ill patients without brain injury. Shock 2006; 26: 20-4. (Pubitemid 44297001)
126. Hsu AA, Fenton K, Weinstein S, Carpenter J , Dalton H, Bell MJ. Neurological injury markers in children with septic shock. Pediatr Crit Care Med 2008; 9: 245-51. (Pubitemid 351677679)
127. Wojtczak-Soska K, Lelonek M. S-100B protein: an early prognostic marker after cardiac arrest. Cardiol J 2010; 17: 532-6.
128. Mazzini GS, Schaf DV, Vinadfi ER, et al. Increased S100B serum levels in dilated cardiomyopathy patients. J Card Fail 2007; 13: 850-4. (Pubitemid 350225589)
129. Lange RT, Brubacher J R, Iverson GL, Procyshyn RM, Mitrovic S. Differential effects of alcohol intoxication on S100B levels following traumatic brain injury. J Trauma 2010; 68:1065-71.
130. Biberthaler P, Mussack T, Wiedemann E, et al. Influence of alcohol exposure on S-100b serum levels. Acta Neurochir Suppl 2000; 76:177-9.
131. Biberthaler P, Mussack T, Wiedemann E, et al. Elevated serum levels of S-100B reflect the extent of brain injury in alcohol intoxicated patients after mild head trauma. Shock 2001; 16: 97-101. (Pubitemid 33596741)
132. Ben Abdesselam O, Vally J , Adem C, Foglietti MJ, Beaudeux J L. Reference values for serum S-100B protein depend on the race of individuals. Clin Chem 2003; 49: 836-7. (Pubitemid 36513275)
133. Andersen KE, Malbach HI. Black and white human skin differences. J Am Acad Dermatol 1979; 1: 276-82. (Pubitemid 11159976)